Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma

J Invest Dermatol. 2018 Jul;138(7):1573-1581. doi: 10.1016/j.jid.2018.02.015. Epub 2018 Feb 23.

Abstract

Primary cutaneous marginal zone lymphoma (PCMZL) represents an indolent subtype of non-Hodgkin lymphoma that is clinically characterized by slowly growing skin tumors with a very low propensity for systemic dissemination. The underlying genetic basis of PCMZL has not been comprehensively elucidated. To gain deeper insight into the molecular pathogenesis of PCMZL, we performed hybridization-based panel sequencing of 38 patients with well-characterized PCMZL. In 32 of the 38 patients, we identified genetic alterations within 39 selected target genes. The most frequently detected alterations (24/38 patients, 63.2%) affected the FAS gene, of which 22 patients harbored alterations, which affect the functionally relevant death domain of the apoptosis-regulating FAS/CD95 protein in a dominant-negative manner. In addition, we identified highly recurrent mutations in three other genes, namely SLAMF1, SPEN, and NCOR2. Our molecular data suggest that apoptosis defects provide the molecular basis of the observed clinical features of PCMZL, which commonly presents with only slowly growing skin tumors, reflecting its invariably indolent behavior. From a diagnostic point of view, highly recurrent FAS mutations in PCMZL presumably separate this indolent lymphoma entity from pseudolymphoma, and this adds adjunctive discriminatory features at a molecular level.

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Death Domain / genetics
  • Diagnosis, Differential
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Lymphoma, B-Cell, Marginal Zone / diagnosis
  • Lymphoma, B-Cell, Marginal Zone / genetics*
  • Mutation
  • Pseudolymphoma / diagnosis
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / genetics*
  • fas Receptor / genetics*

Substances

  • Biomarkers, Tumor
  • FAS protein, human
  • fas Receptor